Last updated April 29, 2026
As of April 2026, Phase 2/3 Study ‘302’ has reported positive topline results (April 27, 2026). A second pivotal male trial (Study ‘304’, 536 patients) is fully enrolled with results expected H2 2026. If Study ‘304’ confirms Study ‘302’ findings, Veradermics plans to file an NDA with the FDA in early 2027, targeting potential approval in late 2027 or early 2028. The drug is not yet approved and is not available for purchase.
From trial completion to market — typical steps
- Database lock & statistical analysis (≈ 3‒6 months)
Cleaning, adjudication and final analysis of efficacy/safety data. - NDA / MAA preparation (≈ 3 months)
Common Technical Document assembly, manufacturing dossier, labelling. - Regulatory review
• FDA standard review: 10 months
• FDA priority review (if granted): 6 months
• EMA (centralised): ~12 months (clock-stop not included) - First marketing authorisation → sequential filings in other regions.
- Commercial launch: manufacturing scale-up, pricing, reimbursement.
With Study ‘302’ results confirmed positive (April 2026) and Study ‘304’ results expected H2 2026, an optimistic scenario places NDA filing in early 2027 and FDA approval in late 2027 (priority review). A conservative scenario (standard review + potential queries from Study ‘304’) shifts first market launch to mid-2028.
Key uncertainties
- Study ‘302’: ✓ met all primary and key secondary endpoints (April 27, 2026). Study ‘304’: confirmatory results expected H2 2026 — outcome still pending.
- Safety profile: unforeseen cardiovascular or endocrine signals could delay approval.
- Manufacturing readiness: scale-up of an oral solid dose is usually straightforward but still subject to GMP inspections.
Update archive
| Date | Event | Link |
|---|---|---|
| 2026-04-27 | Study ‘302’ positive topline results announced. All endpoints met; +30.3–33.0 hairs/cm² vs +7.3 placebo; 79–86% patient improvement; no cardiac AESIs. Shares +48%. | Business Wire |
| 2026-02-09 | Enrollment completed in Study ‘304’ (second Phase 3 male trial, 536 patients). ~1,000 male patients enrolled across both studies. | Business Wire |
| 2025-10-16 | USD 150M Series C financing announced to advance VDPHL01 through multiple Phase 3 trials. | Press release |
| 2025-10-22 | ClinicalTrials.gov record confirms Active, not recruiting. | NCT06724614 |
| 2025-09-03 | Status changed from Recruiting → Active, not recruiting. | NCT06724614 |
| 2025-03-04 | Protocol v2.0 uploaded (dose‑adjustment arm). | NCT06724614 |
| 2024-11-06 | First participant dosed; trial start. | NCT06724614 |
How to track future updates
- Bookmark the trial registry entry: NCT06724614.
- Subscribe to Veradermics’ press releases or RSS feed.
- Monitor FDA “Drugs@FDA” database after NDA submission.
Sources
- ClinicalTrials.gov — NCT06724614 (accessed 22 Oct 2025)
- Veradermics Investor Deck Q2 2025 (slide 14) [accessed 22 Oct 2025]
- FDA Guidance for Industry: Review Timelines (2019) [accessed 22 Oct 2025]